AbbVie U-Turns On Dong-A’s MerTK Program After Development Delays

 
• By Jung Won Shin

After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.

Uturn
Dong-A Yet To Determine New Development Plans after abbvie u-turn • Source: Alamy

More from South Korea

More from Focus On Asia